Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chris Viehbacher takes the helm at Sanofi-Aventis

This article was originally published in Scrip

Executive Summary

Chris Viehbacher has taken up his role as Sanofi-Aventis's CEO after leaving GlaxoSmithKlinein September. Mr Viehbacher, who holds German and Canadian nationalities, was previously president of GSK's pharmaceutical operations in North America. He takes over at Sanofi-Aventis from Gerard Le Fur. Mr Viebacher will receive a €2.2 million indemnity and 65,000 consideration-free Sanofi-Aventis shares and 200,000 Sanofi-Aventis stock options in compensation for the benefits that he surrendered after leaving GSK.

Advertisement
Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007526

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel